{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:21:14Z","timestamp":1792023674006,"version":"4.4.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s41030-024-00280-0","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T08:20:38Z","timestamp":1733905238000},"page":"7-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u0395osinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?"],"prefix":"10.1007","volume":"11","author":[{"given":"Konstantinos","family":"Bartziokas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriana I.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Rovina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Loukides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-6253","authenticated-orcid":false,"given":"Paschalis","family":"Steiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"280_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-med-080919-112707","volume":"72","author":"MC Ferrera","year":"2021","unstructured":"Ferrera MC, Labaki WW, Han MK. Advances in chronic obstructive pulmonary disease. Annu Rev Med. 2021;72:119\u201334.","journal-title":"Annu Rev Med"},{"key":"280_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2147\/COPD.S129787","volume":"12","author":"M Zysman","year":"2017","unstructured":"Zysman M, Deslee G, Caillaud D, Chanez P, Escamilla R, Court-Fortune I, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1819\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"280_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1513\/pats.200802-014ET","volume":"5","author":"V Kim","year":"2008","unstructured":"Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:478\u201385.","journal-title":"Proc Am Thorac Soc"},{"key":"280_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2040622315609251","volume":"7","author":"L George","year":"2016","unstructured":"George L, Brightling CE. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis. 2016;7:34\u201351.","journal-title":"Ther Adv Chronic Dis"},{"key":"280_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/14656566.2019.1701656","volume":"21","author":"TE Albertson","year":"2020","unstructured":"Albertson TE, Chenoweth JA, Pearson SJ, Murin S. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). Expert Opin Pharmacother. 2020;21:213\u201331.","journal-title":"Expert Opin Pharmacother"},{"key":"280_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12050708","author":"E Fouka","year":"2022","unstructured":"Fouka E, Papaioannou AI, Hillas G, Steiropoulos P. Asthma\u2013COPD overlap syndrome: recent insights and unanswered questions. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12050708.","journal-title":"J Pers Med"},{"key":"280_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.chest.2021.09.036","volume":"161","author":"C Leung","year":"2022","unstructured":"Leung C, Sin DD. Asthma\u2013COPD overlap: what are the important questions? Chest. 2022;161:330\u201344.","journal-title":"Chest"},{"key":"280_CR8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5455\/msm.2012.24.100-105","volume":"24","author":"V Cukic","year":"2012","unstructured":"Cukic V, Lovre V, Dragisic D, Ustamujic A. Asthma and chronic obstructive pulmonary disease (COPD)\u2014differences and similarities. Mater Sociomed. 2012;24:100\u20135.","journal-title":"Mater Sociomed"},{"key":"280_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/thx.2004.032516","volume":"60","author":"CE Brightling","year":"2005","unstructured":"Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60:193\u20138.","journal-title":"Thorax"},{"key":"280_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","volume":"76","author":"B David","year":"2021","unstructured":"David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76:188\u201395.","journal-title":"Thorax"},{"key":"280_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04590-2020","author":"VS Benson","year":"2022","unstructured":"Benson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.04590-2020.","journal-title":"Eur Respir J"},{"key":"280_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/COPD.S234823","volume":"15","author":"S Zhang","year":"2020","unstructured":"Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417\u201338.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"280_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","volume":"3","author":"S Pascoe","year":"2015","unstructured":"Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435\u201342.","journal-title":"Lancet Respir Med"},{"key":"280_CR14","doi-asserted-by":"publisher","first-page":"20220779","DOI":"10.1515\/biol-2022-0779","volume":"18","author":"C Wu","year":"2023","unstructured":"Wu C. Research progress of serum eosinophil in chronic obstructive pulmonary disease and asthma. Open Life Sci. 2023;18:20220779.","journal-title":"Open Life Sci"},{"key":"280_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejphar.2005.12.064","volume":"533","author":"JJ Smit","year":"2006","unstructured":"Smit JJ, Lukacs NW. A closer look at chemokines and their role in asthmatic responses. Eur J Pharmacol. 2006;533:277\u201388.","journal-title":"Eur J Pharmacol"},{"key":"280_CR16","first-page":"39","volume":"1","author":"S Saha","year":"2006","unstructured":"Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:39\u201347.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"280_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fimmu.2014.00570","volume":"5","author":"F Davoine","year":"2014","unstructured":"Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol. 2014;5:570.","journal-title":"Front Immunol"},{"key":"280_CR18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/all.13760","volume":"74","author":"PJ Barnes","year":"2019","unstructured":"Barnes PJ. Inflammatory endotypes in COPD. Allergy. 2019;74:1249\u201356.","journal-title":"Allergy"},{"key":"280_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.742","volume":"9","author":"A Cook","year":"2021","unstructured":"Cook A, Harrington J, Simpson JL, Wark P. Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab. Respirol Case Rep. 2021;9: e00743.","journal-title":"Respirol Case Rep"},{"key":"280_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111808","author":"MC Gestal","year":"2020","unstructured":"Gestal MC, Blas-Machado U, Johnson HM, Rubin LN, Dewan KK, Bryant C, et al. Disrupting immunosuppression reveals a role for eosinophils in coordinating the adaptive immune response in the respiratory tract. Microorganisms. 2020. https:\/\/doi.org\/10.3390\/microorganisms8111808.","journal-title":"Microorganisms"},{"key":"280_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.amjms.2017.03.020","volume":"354","author":"JC Weissler","year":"2017","unstructured":"Weissler JC. Eosinophilic lung disease. Am J Med Sci. 2017;354:339\u201349.","journal-title":"Am J Med Sci"},{"key":"280_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","volume":"192","author":"SH Siddiqui","year":"2015","unstructured":"Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:523\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651\u20139.","journal-title":"Lancet"},{"key":"280_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3109\/02770903.2012.713428","volume":"49","author":"SL Spector","year":"2012","unstructured":"Spector SL, Tan RA. Is a single blood eosinophil count a reliable marker for \u201ceosinophilic asthma?\u201d J Asthma. 2012;49:807\u201310.","journal-title":"J Asthma"},{"key":"280_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaci.2010.04.011","volume":"126","author":"F Roufosse","year":"2010","unstructured":"Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126:39\u201344.","journal-title":"J Allergy Clin Immunol"},{"key":"280_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0084-2023","author":"S Lea","year":"2023","unstructured":"Lea S, Higham A, Beech A, Singh D. How inhaled corticosteroids target inflammation in COPD. Eur Respir Rev. 2023. https:\/\/doi.org\/10.1183\/16000617.0084-2023.","journal-title":"Eur Respir Rev"},{"key":"280_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","volume":"206","author":"D Singh","year":"2022","unstructured":"Singh D, Agusti A, Martinez FJ, Papi A, Pavord ID, Wedzicha JA, et al. Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022 review. Am J Respir Crit Care Med. 2022;206:17\u201324.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S2213-2600(23)00298-9","volume":"12","author":"S Ramakrishnan","year":"2024","unstructured":"Ramakrishnan S, Jeffers H, Langford-Wiley B, Davies J, Thulborn SJ, Mahdi M, et al. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial. Lancet Respir Med. 2024;12:67\u201377.","journal-title":"Lancet Respir Med"},{"key":"280_CR29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00427-2018","author":"T Southworth","year":"2018","unstructured":"Southworth T, Beech G, Foden P, Kolsum U, Singh D. The reproducibility of COPD blood eosinophil counts. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.00427-2018.","journal-title":"Eur Respir J"},{"key":"280_CR30","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697\u2013700.","journal-title":"Eur Respir J"},{"key":"280_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","volume":"193","author":"S Vedel-Krogh","year":"2016","unstructured":"Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193:965\u201374.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201104-0597oc","author":"M Bafadhel","year":"2011","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease [internet]. Am J Respir Crit Care Med. 2011. https:\/\/doi.org\/10.1164\/rccm.201104-0597oc.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR33","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMoa032158","volume":"350","author":"JC Hogg","year":"2004","unstructured":"Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645\u201353.","journal-title":"N Engl J Med"},{"key":"280_CR34","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","volume":"5","author":"AT Hastie","year":"2017","unstructured":"Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5:956\u201367.","journal-title":"Lancet Respir Med"},{"key":"280_CR35","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1183\/09031936.00146306","volume":"29","author":"R Siva","year":"2007","unstructured":"Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29:906\u201313.","journal-title":"Eur Respir J"},{"key":"280_CR36","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1164\/rccm.201708-1684LE","volume":"197","author":"G Turato","year":"2018","unstructured":"Turato G, Semenzato U, Bazzan E, Biondini D, Tin\u00e8 M, Torrecilla N, et al. blood eosinophilia neither reflects tissue eosinophils nor worsens clinical outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197:1216\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/0091-6749(93)90078-T","volume":"92","author":"JY Lacoste","year":"1993","unstructured":"Lacoste JY, Bousquet J, Chanez P, Van Vyve T, Simony-Lafontaine J, Lequeu N, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92:537\u201348.","journal-title":"J Allergy Clin Immunol"},{"key":"280_CR38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2019","author":"P Jogdand","year":"2020","unstructured":"Jogdand P, Siddhuraj P, Mori M, Sanden C, J\u00f6nsson J, Walls AF, et al. Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00110-2019.","journal-title":"Eur Respir J"},{"key":"280_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S2213-2600(15)00254-4","volume":"3","author":"ED Bateman","year":"2015","unstructured":"Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma\u2013COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3:719\u201328.","journal-title":"Lancet Respir Med"},{"key":"280_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12931-019-1198-4","volume":"20","author":"M Hosseini","year":"2019","unstructured":"Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma\u2013COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019;20:229.","journal-title":"Respir Res"},{"key":"280_CR41","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.2147\/COPD.S374079","volume":"17","author":"J Peng","year":"2022","unstructured":"Peng J, Wang M, Wu Y, Shen Y, Chen L. Clinical indicators for asthma\u2013COPD overlap: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2022;17:2567\u201375.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"280_CR42","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.2147\/COPD.S170743","volume":"13","author":"M B\u00e9langer","year":"2018","unstructured":"B\u00e9langer M, Couillard S, Courteau J, Lariv\u00e9e P, Poder TG, Carrier N, et al. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Int J Chron Obstruct Pulmon Dis. 2018;13:3045\u201354.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"280_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/1354750X.2021.1903998","volume":"26","author":"K Kostikas","year":"2021","unstructured":"Kostikas K, Papathanasiou E, Papaioannou AI, Bartziokas K, Papanikolaou IC, Antonakis E, et al. Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study. Biomarkers. 2021;26:354\u201362.","journal-title":"Biomarkers"},{"key":"280_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040686","author":"K Bartziokas","year":"2023","unstructured":"Bartziokas K, Papathanasiou E, Papaioannou AI, Papanikolaou I, Antonakis E, Makou I, et al. Eosinopenia as a prognostic biomarker for noninvasive ventilation use in COPD exacerbations. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13040686.","journal-title":"J Pers Med"},{"key":"280_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","volume":"150","author":"M Bafadhel","year":"2016","unstructured":"Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JEA, Morgan MD, Brightling CE, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150:320\u20138.","journal-title":"Chest"},{"key":"280_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107501","volume":"222","author":"H Liu","year":"2024","unstructured":"Liu H, Xie Y, Huang Y, Luo K, Gu Y, Zhang H, et al. The association between blood eosinophils and clinical outcome of acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2024;222: 107501.","journal-title":"Respir Med"},{"key":"280_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12931-018-0840-x","volume":"19","author":"SH Shin","year":"2018","unstructured":"Shin SH, Park HY, Kang D, Cho J, Kwon SO, Park JH, et al. Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respir Res. 2018;19:134.","journal-title":"Respir Res"},{"key":"280_CR48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01162-2017","author":"C Casanova","year":"2017","unstructured":"Casanova C, Celli BR, de Torres JP, Mart\u00ednez-Gonzalez C, Cosio BG, Pinto-Plata V, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017. https:\/\/doi.org\/10.1183\/13993003.01162-2017.","journal-title":"Eur Respir J"},{"key":"280_CR49","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141:2037-47.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"280_CR50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02240-2023","author":"DMG Halpin","year":"2024","unstructured":"Halpin DMG, Healey H, Skinner D, Carter V, Pullen R, Price D. Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.02240-2023.","journal-title":"Eur Respir J"},{"key":"280_CR51","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thx.2010.135574","volume":"67","author":"HL Petsky","year":"2012","unstructured":"Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012;67:199\u2013208.","journal-title":"Thorax"},{"key":"280_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","volume":"113","author":"TN Tran","year":"2014","unstructured":"Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol. 2014;113:19\u201324.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"280_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","volume":"71","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD. Thorax. 2016;71:118\u201325.","journal-title":"Thorax"},{"key":"280_CR54","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","volume":"47","author":"NC Barnes","year":"2016","unstructured":"Barnes NC, Sharma R, Lettis S, Calverley PMA. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47:1374\u201382.","journal-title":"Eur Respir J"},{"key":"280_CR55","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"},{"key":"280_CR56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","volume":"4","author":"H Watz","year":"2016","unstructured":"Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390\u20138.","journal-title":"Lancet Respir Med"},{"key":"280_CR57","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222\u201334.","journal-title":"N Engl J Med"},{"key":"280_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","volume":"21","author":"TH Harries","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21:3.","journal-title":"Respir Res"},{"key":"280_CR59","doi-asserted-by":"publisher","first-page":"204062232110287","DOI":"10.1177\/20406223211028768","volume":"12","author":"T Liu","year":"2021","unstructured":"Liu T, Xiang Z-J, Hou X-M, Chai J-J, Yang Y-L, Zhang X-T. Blood eosinophil count-guided corticosteroid therapy and as a prognostic biomarker of exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:20406223211028770.","journal-title":"Ther Adv Chronic Dis"},{"key":"280_CR60","unstructured":"2024 GOLD Report [Internet]. Global initiative for chronic obstructive lung disease\u2014GOLD. 2023. https:\/\/goldcopd.org\/2024-gold-report\/. Accessed Jul 11, 2024"},{"key":"280_CR61","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12931-024-02918-8","volume":"25","author":"S Muro","year":"2024","unstructured":"Muro S, Kawayama T, Sugiura H, Seki M, Duncan EA, Bowen K, et al. Benefits of budesonide\/glycopyrronium\/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history. Respir Res. 2024;25:297.","journal-title":"Respir Res"},{"key":"280_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.3790","author":"AG Mathioudakis","year":"2024","unstructured":"Mathioudakis AG, Bate S, Sivapalan P, St\u00e6hr Jensen J-U, Singh D, Vestbo J. Rethinking blood eosinophils for assessing ICS response in COPD: a post hoc analysis from FLAME. Chest. 2024. https:\/\/doi.org\/10.1016\/j.chest.2024.06.3790.","journal-title":"Chest"},{"key":"280_CR63","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","volume":"4","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016;4:731\u201341.","journal-title":"Lancet Respir Med"},{"key":"280_CR64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s41030-024-00255-1","volume":"10","author":"B Aggarwal","year":"2024","unstructured":"Aggarwal B, Jones P, Casas A, Gomes M, Juthong S, Litewka D, et al. Association between increased risk of pneumonia with ICS in COPD: a continuous variable analysis of patient factors from the IMPACT study. Pulm Ther. 2024;10:183\u201392.","journal-title":"Pulm Ther"},{"key":"280_CR65","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","volume":"186","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pupt.2016.03.004","volume":"37","author":"L Serafino-Agrusa","year":"2016","unstructured":"Serafino-Agrusa L, Scichilone N, Spatafora M, Battaglia S. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: a case-control study. Pulm Pharmacol Ther. 2016;37:89\u201394.","journal-title":"Pulm Pharmacol Ther"},{"key":"280_CR67","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1183\/09031936.00062614","volume":"44","author":"M Bafadhel","year":"2014","unstructured":"Bafadhel M, Davies L, Calverley PMA, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44:789\u201391.","journal-title":"Eur Respir J"},{"key":"280_CR68","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","volume":"7","author":"P Sivapalan","year":"2019","unstructured":"Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7:699\u2013709.","journal-title":"Lancet Respir Med"},{"key":"280_CR69","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","volume":"176","author":"P Flood-Page","year":"2007","unstructured":"Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062\u201371.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR70","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O\u2019Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167:1655\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"280_CR71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549\u201356.","journal-title":"Lancet Respir Med"},{"key":"280_CR72","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132:1086-96.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"280_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/ACI.0000000000000251","volume":"16","author":"G Varricchi","year":"2016","unstructured":"Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. 2016;16:186\u2013200.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"280_CR74","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377:1613\u201329.","journal-title":"N Engl J Med"},{"key":"280_CR75","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","volume":"2","author":"CE Brightling","year":"2014","unstructured":"Brightling CE, Bleecker ER, Panettieri RA Jr, Bafadhel M, She D, Ward CK, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2:891\u2013901.","journal-title":"Lancet Respir Med"},{"key":"280_CR76","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","volume":"8","author":"GJ Criner","year":"2020","unstructured":"Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med. 2020;8:158\u201370.","journal-title":"Lancet Respir Med"},{"key":"280_CR77","unstructured":"Trial [Internet]. https:\/\/cdek.pharmacy.purdue.edu\/trial\/NCT04098718\/. Accessed Jul 12, 2024"},{"key":"280_CR78","first-page":"CD13432","volume":"12","author":"T Donovan","year":"2020","unstructured":"Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;12:CD13432.","journal-title":"Cochrane Database Syst Rev"},{"key":"280_CR79","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/WOX.0b013e31821188e0","volume":"4","author":"EL Rael","year":"2011","unstructured":"Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. World Allergy Organ J. 2011;4:54\u201364.","journal-title":"World Allergy Organ J"},{"key":"280_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31\u201344.","journal-title":"Lancet"},{"key":"280_CR81","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389:205\u201314.","journal-title":"N Engl J Med"},{"key":"280_CR82","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390:2274\u201383.","journal-title":"N Engl J Med"},{"key":"280_CR83","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew FY, Girard J-P, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16:676\u201389.","journal-title":"Nat Rev Immunol"},{"key":"280_CR84","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9:1288\u201398.","journal-title":"Lancet Respir Med"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00280-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-024-00280-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00280-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:12:50Z","timestamp":1740499970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-024-00280-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s41030-024-00280-0","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paschalis Steiropoulos is an Editorial Board member of Pulmonary Therapy. Paschalis Steiropoulos was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Konstantinos Bartziokas, Andriana I Papaioannou, Nikoletta Rovina, Georgia Loukides, and Stelios Loukides have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}